Published in Neuro Oncol on March 21, 2008
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
The molecular profile of microglia under the influence of glioma. Neuro Oncol (2012) 2.38
Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res (2010) 1.60
Tumor microenvironment and progression. J Surg Oncol (2011) 1.54
Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci U S A (2010) 1.41
Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance. Int J Cancer (2010) 1.24
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol (2015) 1.15
Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech (2010) 1.13
Tumor microenvironment in the brain. Cancers (Basel) (2012) 1.12
The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS (2011) 1.08
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol (2013) 1.05
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol (2013) 1.04
MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro Oncol (2015) 0.93
A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J Clin Oncol (2012) 0.89
Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. J Biol Chem (2010) 0.87
CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth. Transl Oncol (2011) 0.85
Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol (2015) 0.84
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget (2016) 0.83
Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World J Urol (2013) 0.81
Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma. Oncol Lett (2014) 0.81
Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin Cancer Res (2013) 0.81
S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncol Lett (2015) 0.79
Glioblastoma: Defining Tumor Niches. Trends Cancer (2015) 0.78
The role of the cell-cell interactions in cancer progression. J Cell Mol Med (2015) 0.75
Deficiency in matrix metalloproteinase-2 results in long-term vascular instability and regression in the injured mouse spinal cord. Exp Neurol (2016) 0.75
A Novel Role of Cab45-G in Mediating Cell Migration in Cancer Cells. Int J Biol Sci (2016) 0.75
The biology of VEGF and its receptors. Nat Med (2003) 32.13
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol (2007) 10.17
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol (2005) 4.54
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol (2004) 4.16
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev (1996) 2.06
Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res (1998) 1.78
Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood (2004) 1.77
Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol (2003) 1.74
Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst (1993) 1.49
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer (2003) 1.45
Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys (1993) 1.39
Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol (2005) 1.32
The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol (2003) 1.30
Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol (1996) 1.13
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun (2005) 1.13
Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol (2005) 1.10
Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res (2003) 1.02
Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep (2006) 0.97
The IGF system and bone. J Endocrinol Invest (2005) 0.95
Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol (2002) 0.92
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 4.57
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature (2008) 3.05
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Nanos and Pumilio are essential for dendrite morphogenesis in Drosophila peripheral neurons. Curr Biol (2004) 2.05
Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A (2005) 1.97
Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79
Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood (2004) 1.77
Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell (2011) 1.67
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res (2011) 1.64
Tumor microenvironment and progression. J Surg Oncol (2011) 1.54
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol (2007) 1.53
The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol (2006) 1.40
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res (2013) 1.35
EXPANDS: expanding ploidy and allele frequency on nested subpopulations. Bioinformatics (2013) 1.33
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol (2011) 1.31
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Transformation of the microvascular system during multistage tumorigenesis. Int J Cancer (2002) 1.30
CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol (2004) 1.26
Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res (2004) 1.19
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol (2009) 1.17
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15
Ovol1 regulates meiotic pachytene progression during spermatogenesis by repressing Id2 expression. Development (2005) 1.12
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
Asymmetric cell division of stem and progenitor cells during homeostasis and cancer. Cell Mol Life Sci (2013) 1.11
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol (2009) 1.06
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol (2013) 1.05
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res (2006) 1.04
Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest (2008) 1.02
Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res (2006) 1.01
Invading macrophages play a major role in the liver progenitor cell response to chronic liver injury. J Hepatol (2010) 1.00
Laminin-5 activates extracellular matrix production and osteogenic gene focusing in human mesenchymal stem cells. Matrix Biol (2006) 1.00
The Drosophila caspase DRONC is required for metamorphosis and cell death in response to irradiation and developmental signals. Mech Dev (2005) 0.99
Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp Cell Res (2011) 0.98
Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas. NMR Biomed (2009) 0.98
Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc Med (2009) 0.98
Proteoglycans and their roles in brain cancer. FEBS J (2013) 0.98
Tumor growth or regression: powered by inflammation. J Leukoc Biol (2006) 0.96
X-ray crystallography and magnetic studies of a stable macrocyclic tetranitroxide. Intramolecular dimer of nitroxides in a constrained geometry of the upper rim of calix[4]arene. J Am Chem Soc (2003) 0.95
Asymmetric localization of the adaptor protein Miranda in neuroblasts is achieved by diffusion and sequential interaction of Myosin II and VI. J Cell Sci (2008) 0.95
Modulation of g protein signaling normalizes tumor vessels. Cancer Res (2009) 0.95
Secreted frizzled-related protein 4: an angiogenesis inhibitor. Am J Pathol (2010) 0.94
Studying enzymatic bioreactions in a millisecond microfluidic flow mixer. Biomicrofluidics (2012) 0.93
Comparing the protein expression profiles of human mesenchymal stem cells and human osteoblasts using gene ontologies. Stem Cells Dev (2005) 0.93
Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res (2011) 0.93
Intracranial metastasis of a primary scalp angiosarcoma. Case illustration. J Neurosurg (2002) 0.92
Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol (2009) 0.91
Modulation of the "blood-tumor" barrier improves immunotherapy. Cell Cycle (2008) 0.91
Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. Transl Oncol (2009) 0.91
Regulator of G-protein signaling 5 controls blood pressure homeostasis and vessel wall remodeling. Circ Res (2013) 0.90
Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes. Exp Ther Med (2013) 0.89
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol (2010) 0.89
CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen. Proc Natl Acad Sci U S A (2006) 0.88
Remodeling of tumor stroma and response to therapy. Cancers (Basel) (2012) 0.87
Focusing of gene expression as the basis of stem cell differentiation. Stem Cells Dev (2005) 0.86
Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle (2006) 0.85
Sublineage structure analysis of Mycobacterium tuberculosis complex strains using multiple-biomarker tensors. BMC Genomics (2011) 0.85
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev (2006) 0.84
Dronc caspase exerts a non-apoptotic function to restrain phospho-Numb-induced ectopic neuroblast formation in Drosophila. Development (2011) 0.83
Matrigel basement membrane matrix influences expression of microRNAs in cancer cell lines. Biochem Biophys Res Commun (2012) 0.82
Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol Lett (2009) 0.81
HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed (2014) 0.81
Intratumoral TNFα improves immunotherapy. Oncoimmunology (2012) 0.79
Chapter 3. Bone marrow-derived vascular progenitors and proangiogenic monocytes in tumors. Methods Enzymol (2008) 0.79
Novel target for peptide-based imaging and treatment of brain tumors. Mol Cancer Ther (2014) 0.78
Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. Adv Exp Med Biol (2014) 0.77
End-to-end differential contactless conductivity sensor for microchip capillary electrophoresis. Anal Chem (2010) 0.77
Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'. Pharmacogenomics (2009) 0.77
Examining the sublineage structure of Mycobacterium tuberculosis complex strains with multiple-biomarker tensors. Proceedings (IEEE Int Conf Bioinformatics Biomed) (2010) 0.75
Ceramic capillary electrophoresis chip for the measurement of inorganic ions in water samples. Analyst (2010) 0.75
Identifying Mechanisms of Bevacizumab Evasion in Human Glioblastoma: 971. Neurosurgery (2009) 0.75
[Preliminary study on pro-apoptotic gene BAD of Schistosoma japonicum]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi (2015) 0.75
Urinary RBP and NGAL Levels are Associated with Nephropathy in Patients with Type 2 Diabetes. Cell Physiol Biochem (2017) 0.75